Hutchison MediPharma Enters Cancer Therapy Collaboration with Lilly

摘要

Hutchison MediPharma Limited (HMP), an REtD company majority owned by Chi-Med has entered into a licensing, co-development, and commercialization agreement in China with Eli Lilly and Company (Lilly) for Fruquintinib (HMPL-013), a targeted oncology therapy for the potential treatment of various types of solid tumors. Fruquintinib, a selective inhibitor of the Vascular Endothelial Growth Factor (VEGF) receptor tyrosine kinases, was discovered by HMP and is currently in Phase II testing in China.